Product Reports Resources Pricing Login Book a demo

Arcellx

Biotech & Life Sciences · Gaithersburg, United States · Founded 2015 · IPO 2022

Arcellx is a clinical-stage biotechnology company focused on developing innovative immunotherapies to transform cell therapy. The company operates in the biopharmaceutical sector, targeting diseases that can be treated through advanced cell therapy techniques. Arcellx's primary clients include healthcare providers, research institutions, and patients in need of cutting-edge treatments for serious conditions. The business model revolves around the research, development, and commercialization of proprietary immunotherapy products. Revenue is generated through partnerships, licensing agreements, and eventual product sales upon regulatory approval. Arcellx aims to address unmet medical needs by leveraging its expertise in cell therapy to create effective and safe treatment options. Keywords: biotechnology, immunotherapy, cell therapy, clinical-stage, biopharmaceutical, healthcare, research, development, commercialization, treatment

Valuation $6.33B
Revenue $22M
Total funding $100–500M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue
Featured in
News Gilead to buy German biotech Tubulis for up to $5B to bolster cancer drug pipeline Apr 7, 2026 News Merck pays $6.7B for Terns Pharma to plug its Keytruda gap Mar 25, 2026 News Gilead to buy Arcellx for $7.8B to secure cancer therapy anito-cel Feb 23, 2026

Investors

23 investors on Arcellx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 11 investors entered at this stage
NEA
Novo Ventures
Aju IB Investment
Quan Capital
Takeda Ventures
Clough Capital Partners
Mirae Asset Capital
SR One
Mirae Asset Venture Investment
Novo Holdings
LG Technology Ventures
Series B+ 12 investors entered at this stage
Samsara BioCapital
CAM Capital
Soleus Capital
Terra Magnum Capital Partners
Sixty Degree Capital
Cambrian BioPharma
CaaS Capital Management
Surveyor Capital
Adage Capital
Suvretta Capital Management
Asymmetry
Kite Pharma

Global footprint

Where Arcellx has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
4.9K monthly visits
across markets
🇺🇸 United States67.3%
🇮🇳 India16.3%
🇬🇧 United Kingdom14.3%
Top 3 markets shown

Talent graph

The shape of Arcellx's talent

Dealroom maps Arcellx's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

11 team members profilednamed & role-tagged by Dealroom
192 employeestotal headcount
5 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Arcellx's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$14M patent portfolio · 9 active families

Estimated portfolio value
$14M
0.23% of market cap · 400.2× smaller than top peer Ablynx ($5.8B)
9 active patent families
Where Arcellx innovates Antigen receptorsCAR - Chimeric antigen receptorCellCell biologyCell mediated immunity

Where Arcellx concentrates vs peers

Each axis is a top-10 topic across Arcellx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Arcellx

An AI-synthesized read of the highest-engagement posts about Arcellx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arcellx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles